EVERZOM
EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles. They develop a bioproduction platform to produce extracellular vesicles at a commercial scale in a GMP compliant way for pharmaceutical companies with applications in regenerative medicine and drug delivery. Extracellular vesicles that encompass exosomes, microvesicles, and apoptotic bodies are the tools used by cells to communicate with each other. EVerZom was founded in 2019 and is headquartered in Paris, Ile-de-France, France.
EVERZOM
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1919-07-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.everzom.com
Total Employee:
1+
Status:
Active
Contact:
+33678280120
Email Addresses:
[email protected]
Total Funding:
2.87 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Employees Featured
Founder
Investors List
European Innovation Council
European Innovation Council investment in Grant - EVerZom
Official Site Inspections
http://www.everzom.com Semrush global rank: 10.35 M Semrush visits lastest month: 2
- Host name: 152.228.168.93
- IP address: 152.228.168.93
- Location: Valparaiso United States
- Latitude: 41.4549
- Longitude: -87.0613
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 46383
More informations about "EVerZom"
EVerZom - Crunchbase Company Profile & Funding
EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles. They develop a bioproduction platform to produce …See details»
Our history - Everzom
An important step for EVerZom in December 2019 when Erganeo signed a licensing agreement with EverZom, creating a platform for the production of biological tools, extracellular vesicles, to benefit the emergence of tomorrow’s …See details»
EVerZom Company Profile 2024: Valuation, Funding & Investors
Who are EVerZom’s investors? European Innovation Council Fund, Horizon 2020 SME Instrument, Bpifrance, d'lle de France, and Erganeo are 5 of 10 investors who have invested in …See details»
Discover the EverZom team
At EVerZom, we have successfully overcome the challenge of high-yield, large-scale and cost-effective exosome production and developed a unique proprietary innovation platform. This breakthrough has opened up many potential clinical …See details»
EVerZom - LinkedIn
EVerZom | 4,643 followers on LinkedIn. Revolutionizing healthcare with exosomes focusing on gastrointestinal, liver and kidney regeneration | EverZom is an exosome biotech company developing ...See details»
EVerZom Company Profile - Office Locations, Competitors ... - Craft
EVerZom has 5 employees at their 1 location and $1.32 m in total funding,. See insights on EVerZom including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
EverZom - VentureRadar
EverZom develops a bioproduction platform to manufacture exosomes at clinical grade and large scale based on a unique proprietary technolgy. We provide custom bioprocess development, …See details»
EVerZom - Contacts, Employees, Board Members, Advisors & Alumni
EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles.See details»
EVerZom raises €1.1M to industrialize its exosome …
Nov 30, 2020 EVerZom’s ambition is to transform regenerative medicine and the field of biotherapies thanks to these «super» biological nanoparticles, the exosomes. Paris, November 30, 2020 — EVerZom, a biopharmaceutical …See details»
EVerZom: Therapeutic ambitions in exosome-based biotherapies
Mar 5, 2024 In February 2024, EVerZom participated in the 19th ECCO Congress (European Crohn's and Colitis Organization) in Stockholm, engaging with clinicians and experts involved …See details»
Exclusive license agreement secured with Erganeo for EVerGel, …
Mar 5, 2024 EVerZom participated in the 19th ECCO (European Crohn's and Colitis Organization) Congress, held in Stockholm in February 2024, and presented its advances to …See details»
Innovation platform - Everzom
EVerZom platform is built on four blocks from the cell source to the formulated exosome drug. From adipose derived mesenchymal stem cells to exosomes for patients. Mother cell …See details»
Winner of the European EIC Accelerator program, EVerZom
Paris, 18 November 2021 — EVerZom, a biopharmaceutical company specialized in the biomanufacturing of extracellular vesicles (or exosomes), announced today that it has …See details»
EVerZom achieves first bioproduction of clinical grade stem cell ...
Oct 2, 2024 EVerZom achieves first bioproduction of clinical grade stem cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with …See details»
EVerZom: Therapeutic Ambition in Exosome Biotherapies
Dec 13, 2023 About EVerZom EVerZom, a CNRS/ Université Paris Cité spin-off dedicated to exosomes, was created in 2019 with the aim of becoming a leader in exosome biotherapies.See details»
Partnering - Everzom
We welcome discussions on strategic collaborations with companies that share our ambition to advance novel therapies for patients. Partnerships are and continue to be accelerators for our …See details»
EVerZom achieves first bioproduction of clinical grade stem
Oct 2, 2024 With this first batch, we will carry out the regulatory non-clinical studies, scheduled for early 2025, with the objective of the first-in-human early 2026,’ explains Jeanne Volatron, …See details»
Therapeutic programs - Everzom
EVerZom proprietary therapeutic pipeline. Everzom develops its proprietary pipeline of naïve exosomes in regenerative therapies, large market indications with high unmet medical needs. …See details»
EVerZom achieves first bioproduction of clinical grade stem cell ...
Oct 22, 2024 The disruptive, proprietary technology developed by EVerZom offers a yield 100 times higher than traditional methods. This innovation has just been tech-transferred and …See details»